Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States

• DOI: 10.18553/jmcp.2022.21496
• Publication Date: 2022-12-29T16:03:56Z
• Authors: Maria Dall’Era; Kenneth Kalunian; Michael Eaddy; Augustina Ogbonnaya; Eileen Farrelly; Eric Turowski; Vanessa Birardi; Neil Solomons; Simrat Randhawa; Paola Mina-Osorio
• Keywords: Male; Lupus Erythematosus; Systemic; Health Care Costs; Middle Aged; Mycophenolic Acid; Lupus Nephritis; United States; Kidney Failure; 03 medical and health sciences; 0302 clinical medicine; Pharmaceutical Preparations; Humans; Lupus Erythematosus, Systemic; Kidney Failure, Chronic; Female; Chronic; Glucocorticoids; Retrospective Studies

BACKGROUND: Lupus nephritis (LN) is a common and severe complication of systemic lupus erythematosus (SLE), with approximately 40% patients SLE developing LN. Even treatment, 10%-30% will progress to end-stage renal disease (ESRD). Although many studies have assessed the clinical value low activity in LN, economic implications are less defined. OBJECTIVE: To evaluate treatment utilization health care costs associated active disease, activity, ESRD METHODS: A retrospective analysis Optum pharmacy medical claims data from 2015 2019 was performed included diagnosis (International Classification Diseases, Ninth Revision or Tenth codes 710.0 M32, respectively) additional prespecified criteria for Total payer services commonly prescribed medications were determined periods ESRD. RESULTS: total 21,251 (mean age 60.3 years; 87% female; 55% White 18% Black patients) mean follow-up period 30.6 months included; majority had (67.3%), followed by (51.3%), (10.5%). Glucocorticoids used 2 times more often mycophenolate mofetil 4 vs activity. Glucocorticoids, mofetil, tacrolimus those Mean $4,777 per month $18,084 $2,523 CONCLUSIONS: Treatment burden high Treatments that allow achieve maintain may help improve patient outcomes reduce medication use overall costs. DISCLOSURES: Maria Dall'Era Kenneth Kalunian consultants Aurinia Pharmaceuticals. Eric Turowski, Vanessa Birardi, Neil Solomons, Simrat Randhawa, Paola Mina-Osorio employees stockholders Michael Eaddy former employee Xcenda, LLC. Augustina Ogbonnaya Eileen Farrelly LLC, which contracted Pharmaceuticals assist conduct this study writing manuscript. provided funding preparation role report decision submit publication.